Affymetrix Microarrays Uncover Genetic Mutations in Embryonic Stem Cells Approved for Federally-Funded Research; Scientists Report That Majority of Cells Develop Mutations Over Time
Affymetrix Inc. announced today that a research group led by scientists at Johns Hopkins School of Medicine and the NIH used Affymetrix GeneChip(R) microarrays to discover that eight of the stem cell lines approved for federally-funded research have mutated, raising concern about the use of the remaining 14 approved cell lines in future research or therapeutic applications.
SEC Issues Formal Order in Investigation of Immuncor Subsidiary
Immucor, which manufactures blood-bank instruments, announced last fall that it was being investigated for improprieties. The SEC started its probe after the company self reported to the agency a violation of the books and records requirements of the Foreign Corrupt Practices Act.
SEC Files Civil Complaint Against Former CEO of Transkaryotic Therapies
The former chief executive of Transkaryotic Therapies Inc. is charged in a civil complaint with reassuring investors about failed drug trials to artificially inflate the stock price, then selling off his own shares.
TransGenic Wins Aid For Gene Knockout Mice Research From Hyogo Prefecture
In collaboration with the National Institute of Radiological Sciences (NIRS), TransGenic will analyze gene expressions in embryonic stem (ES) cells of gene knockout mice.
Geron Announces Publication of Studies Demonstrating Engraftment of Human Embryonic Stem Cell-Derived Cardiomyocytes in the Rodent Heart
The results provide proof of concept that transplanted hESC-derived cardiomyocytes survive and retain properties of cardiomyocytes, important for their use in the treatment of heart failure and myocardial infarction.
ViaCell Announces Publication of Preclinical Study Demonstrating That Umbilical Cord Stem Cells Improve Heart Function
ViaCell, Inc. announced today the publication of results of a preclinical study demonstrating that administration of stem cells sourced from umbilical cord blood and using ViaCell’s proprietary process significantly improved heart function in an in vivo model of myocardial infarction (heart attack).
ViaCell Announces Expansion of Amgen Collaboration and License Agreement and New Technology License from Johns Hopkins
ViaCell, Inc. today announced that the Company has licensed from Amgen rights related to the use of recombinant human Granulocyte Colony Stimulating Factor (r- metHuG-CSF) for the development of a cellular therapy product to treat hematological malignancies and genetic diseases.
ImmunoGen, Inc. Announces Sanofi-Aventis Group Extends Research Collaboration; Providing $18.2 Million In Research Support
ImmunoGen, Inc. today announced that Aventis Pharmaceuticals Inc. of the Sanofi-aventis Group has exercised its right to extend the term of its research collaboration with the Company and committed to fund ImmunoGen $18.2 million in research support over the twelve months beginning September 1, 2006.
Immunicon Corporation To Lay Off Workers, Take Charge
Immunicon Corporation , a development-stage company developing and commercializing proprietary cell- and molecular-based human diagnostic and life-science research products with an initial focus on cancer, announced today actions to align staff levels and other expenses with its current commercialization strategy and expectations for near-term revenue growth.
MicroIslet Inc. And The Scripps Research Institute Extend Collaboration In Islet Cell Transplantation Therapies For Treatment Of Insulin Dependent Diabetes
Under the terms of the agreement, MicroIslet and TSRI will continue preclinical studies utilizing MicroIslet’s proprietary technologies.
Mesoblast Commences Bone Regeneration Trials at Colorado State University
Australian adult stem cell company, Mesoblast has commenced preclinical trials at Colorado State University in support of its investigational new drug submissions to the FDA.
Osteotech Introduces New Bio-Implant Product
Osteotech, a provider of human bone and bone connective tissue for transplantation as well as a developer and marketer of biomaterial and implant products for musculoskeletal surgery based in Eatontown, N.J. – has announced the release of its Graftech Lordotic Cervical Spacer.
StemCells, Inc. Receives Manufacturing License for Cell Processing Facility in California
StemCells, Inc. today announced that it has received a manufacturing license for its cell processing facility from the State of California Department of Health Services, Food and Drug Branch. This enables the Company to use its proprietary neural cell therapy product, HuCNS-SC, which is made at its licensed facility, in clinical trials.
Invitrogen Promotes David Onions, Ph.D. to Chief Medical Officer; Scientific Leader to Help Company Transition toward Patient-Centric Support Technologies
In this new role, Dr. Onions will be responsible for guiding the company’s scientific efforts as it moves into areas more closely associated with medical research and closer to patients, such as stem cell technologies, diagnostics support and other clinical studies.
Malachite Management has joined forces with established and reputable authors and publishers to bring you the following market reports outlining the very latest in Cell Therapy, Gene Therapy, and Immunotherapeutic approaches to Cancer.
“Cell Therapy – Technologies, Markets, and Companies” is over 400 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the cell therapy industry worldwide.
For more information, including order forms, please see:
Cell Therapy Report Summary
Cell Therapy Sample Chapter
Cell Therapy Table of Contents Vol. 1 Vol. 2
Cell Therapy Order Form
“Gene Therapy – Technologies, Markets, and Companies” is over 500 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the gene therapy industry worldwide.
For more information, including order forms, please see:
Gene Therapy Report Summary
Gene Therapy Table of Contents Vol. 1 Vol. 2
Gene Therapy Order Form
The Immunotherapy Reports cover the most recent developments in the immunotherapeutic approaches to cancer.
A Shift in Cancer Immunotherapy Strategies?
Immunotherapy Strategies Executive Summary
Immunotherapy Strategies Table of Contents
Future Perspectives in Cancer Immunotherapy
Future Perspectives Executive Summary
Future Perspectives Table of Contents
Immunotherapy Reports Order Form